Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Large-scale proteomic and transcriptomic analyses position the synaptic protein NRN1 as a resilience-linked therapeutic candidate in Alzheimer disease, though validation remains preclinical.

A Large cohort analysis of more than 159,000 adults found greater adherence to multiple healthy dietary patterns—particularly the DASH diet—was linked to a significantly lower risk of subjective cognitive decline in midlife.

The neurologist at LMU Munich University Hospital discussed newly published data supporting plasma brain-derived tau as a dynamic biomarker of infarct growth and treatment response in acute ischemic stroke. [WATCH TIME: 4 minutes]

Pilot trial finds low-dose lithium is safe in mild cognitive impairment, hints at memory benefits, and guides larger studies for Alzheimer prevention.

Neal K. Shah, CEO of CareYaya Health Technologies, discusses how the largest workforce in the US maintains the safety of patients with dementia at home while remaining underpaid and unrecognized.

R. Scott Turner, PhD, MD, director of the memory disorders program at MedStar Georgetown University Hospital, discussed the importance of investigating environmental risk factors in Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Kyle Marden, MD, sports neurologist at Northwestern Medicine, discussed the growing role of sports neurologists and new data supporting the feasibility of quantitative pupillometry as part of a multimodal approach to concussion diagnosis and recovery tracking.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how AI-powered caregiver training platforms like YayaGuide can personalize dementia care education for family caregivers.

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Newly reported data showed that oral valiltramiprosate lowers p-tau217 and links to cognitive and brain-volume benefits in early Alzheimer disease.

Neurology News Network for the week ending January 31, 2025. [WATCH TIME: 4 minutes]

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

Neurology News Network for the week ending January 24, 2025. [WATCH TIME: 4 minutes]

The professor of geriatrics and gerontology at the University of Wisconsin shared insights on prescribing the autoinjector formulation of lecanemab for patients living with Alzheimer disease. [WATCH TIME: 5 minutes]

The senior director at the Banner Alzheimer's Institute talked about findings from the ancillary analyses of the US POINTER Study and the importance of strong recruitment efforts. [WATCH TIME: 5 minutes]

The head of search and evaluation at the Alzheimer's Drug Discovery Foundation discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]

The chief operating officer at Linus Health talked about how brief, digitally administered cognitive assessments enable scalable, earlier identification of cognitive impairment. [WATCH TIME: 4 minutes]

The director at the National Center of Neurology and Psychiatry discussed how biomarker-driven diagnostics and antibody therapies targeting amyloid pathology may be reshaping Alzheimer disease management. [WATCH TIME: 4 minutes]

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.